Hubei Hongyuan Pharmaceutical Technology Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Shuangxi Xu
Chief executive officer
CN¥516.2k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 6.6% |
| Management average tenure | no data |
| Board average tenure | 1.6yrs |
Recent management updates
Recent updates
Does Hubei Hongyuan Pharmaceutical Technology (SZSE:301246) Have A Healthy Balance Sheet?
Dec 18
Subdued Growth No Barrier To Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) With Shares Advancing 38%
Oct 08Hubei Hongyuan Pharmaceutical Technology Co., Ltd.'s (SZSE:301246) P/S Still Appears To Be Reasonable
Aug 23Hubei Hongyuan Pharmaceutical Technology's (SZSE:301246) Soft Earnings Are Actually Better Than They Appear
Apr 29Getting In Cheap On Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SZSE:301246) Is Unlikely
Mar 14CEO
Shuangxi Xu (58 yo)
no data
Tenure
CN¥516,200
Compensation
Mr. Xu Shuangxi serves as Director and General Manager at Hubei Hongyuan Pharmaceutical Technology Co., Ltd.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director and General Manager | no data | CN¥516.20k | 6.62% CN¥ 365.2m | |
| Deputy GM & Non-Independent Director | 1.6yrs | CN¥701.20k | 1.14% CN¥ 63.0m | |
| Deputy GM & Non-Independent Director | 1.6yrs | CN¥423.20k | 0.63% CN¥ 34.9m | |
| Chairman of the Board | no data | CN¥651.10k | 22.75% CN¥ 1.3b | |
| Supervisor | no data | no data | 1.74% CN¥ 95.8m | |
| Chairman of Supervisory Board | no data | no data | 1.51% CN¥ 83.3m | |
| Independent Director | 1.6yrs | CN¥44.30k | no data | |
| Independent Director | 1.6yrs | CN¥44.30k | no data | |
| Independent Director | 1.6yrs | CN¥44.30k | no data | |
| Vice Chairman of the Board | 1.6yrs | CN¥382.20k | no data | |
| Non-Employee Supervisor | 1.6yrs | no data | 1.44% CN¥ 79.7m |
1.6yrs
Average Tenure
58yo
Average Age
Experienced Board: 301246's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 14:41 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|